To our knowledge, this represents the first study demonstrating the functions of BPIFB1 and VTN in the NPC radioresponse, indicating that BPIFB1 might represent a good biomarker for prognosis and a novel therapeutic target for increasing the radiosensitivity of NPC. The gene discussed is VTN; the disease is nasopharyngeal carcinoma.